Shattuck Labs (NASDAQ:STTK) Now Covered by Wedbush

Key Points

• Wedbush has initiated coverage on Shattuck Labs (NASDAQ:STTK) with an "outperform" rating and a target price of $4.00, indicating a potential upside of 142.57% from its previous close.
• The company has a consensus rating of "Moderate Buy" and an average price target of $4.00 based on recent ratings from various analysts.
• Shattuck Labs reported an earnings per share (EPS) of ($0.24), surpassing analysts' expectations, and is focused on developing therapeutics for cancer and autoimmune diseases.

Wedbush assumed coverage on shares of Shattuck Labs (NASDAQ:STTK - Free Report) in a report published on Monday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $4.00 target price on the stock. Wedbush also issued estimates for Shattuck Labs' Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.61) EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($0.28) EPS, FY2028 earnings at ($0.27) EPS and FY2029 earnings at ($0.39) EPS.

STTK has been the subject of several other reports. Needham & Company LLC reiterated a "hold" rating on shares of Shattuck Labs in a research note on Thursday, August 14th. Leerink Partners reduced their target price on Shattuck Labs from $4.00 to $2.00 and set an "outperform" rating for the company in a research note on Thursday, August 14th. Finally, Wall Street Zen upgraded Shattuck Labs to a "hold" rating in a research note on Friday, September 5th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $4.00.

Shattuck Labs Trading Down 3.0%

Shares of NASDAQ:STTK traded down $0.06 during trading on Monday, hitting $1.92. 252,083 shares of the company were exchanged, compared to its average volume of 1,614,250. The stock has a market cap of $91.97 million, a price-to-earnings ratio of -1.59 and a beta of 1.64. Shattuck Labs has a fifty-two week low of $0.69 and a fifty-two week high of $3.95. The firm has a fifty day moving average price of $1.00 and a two-hundred day moving average price of $1.01.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.01. As a group, research analysts predict that Shattuck Labs will post -1.48 EPS for the current year.

Insider Buying and Selling at Shattuck Labs

In related news, Director Orbimed Advisors Llc bought 6,306,127 shares of the business's stock in a transaction dated Monday, August 25th. The stock was purchased at an average cost of $0.87 per share, for a total transaction of $5,486,330.49. Following the transaction, the director owned 5,255,106 shares in the company, valued at $4,571,942.22. The trade was a -600.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mona Ashiya purchased 6,306,127 shares of the firm's stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average price of $0.87 per share, for a total transaction of $5,486,330.49. Following the transaction, the director directly owned 5,255,106 shares of the company's stock, valued at $4,571,942.22. This trade represents a -600.00% increase in their position. The disclosure for this purchase can be found here. Insiders own 12.00% of the company's stock.

Institutional Investors Weigh In On Shattuck Labs

A number of large investors have recently bought and sold shares of STTK. AQR Capital Management LLC increased its holdings in Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company's stock valued at $41,000 after buying an additional 31,355 shares during the period. Qube Research & Technologies Ltd acquired a new stake in shares of Shattuck Labs during the 2nd quarter worth approximately $44,000. Schonfeld Strategic Advisors LLC bought a new position in Shattuck Labs in the fourth quarter valued at approximately $45,000. Nuveen LLC acquired a new position in Shattuck Labs during the first quarter valued at approximately $50,000. Finally, Bridgeway Capital Management LLC raised its position in Shattuck Labs by 147.5% during the second quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company's stock valued at $73,000 after purchasing an additional 55,000 shares in the last quarter. 58.74% of the stock is currently owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.